Transcription of HIGHLIGHTS OF PRESCRIBING INFORMATION …
{{id}} {{{paragraph}}}
Example: air traffic controller
HIGHLIGHTS OF PRESCRIBING INFORMATION …
HIGHLIGHTS OF PRESCRIBING INFORMATION Hypersensitivity to tranexamic acid ( ). These HIGHLIGHTS do not include all the INFORMATION needed to use LYSTEDA safely and effectively. See full PRESCRIBING INFORMATION for -----------------------WARNINGS AND PRECAUTIONS------------------------ LYSTEDA. Concomitant use of LYSTEDA with Factor IX complex concentrates, anti-inhibitor coagulant concentrates or all-trans retinoic acid (oral LYSTEDA (tranexamic acid, USP) Tablets tretinoin) may increase the risk of thrombosis. ( ). Initial Approval: 1986 Visual or ocular adverse effects may occur with LYSTEDA. Immediately discontinue use if visual or ocular symptoms occur. ( ). ---------------------------------RECENT MAJOR CHANGES--------------------- In case of severe allergic reaction, discontinue LYSTEDA and seek Contraindications ( ) 10/2013 immediate medical attention. ( ). Warnings and Precautions ( ) 10/2013 Cerebral edema and cerebral infarction may be caused by use of LYSTEDA in women with subarachnoid hemorrhage.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LYSTEDA safely and effectively. See full prescribing information …
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: